Multifunctional nanocarriers for mammographic quantification of tumor dosing and prognosis of breast cancer therapy

Biomaterials

Volumn 29, Issue 36, 2008, Pages 4815-4822

  Karathanasis, Efstathios ^a   Chan, Leslie ^a   Balusu, Sri R ^a   D'Orsi, Carl J ^b   Annapragada, Ananth V ^c   Sechopoulos, Ioannis ^b   Bellamkonda, Ravi V ^a  

^a Emory University   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c University of Texas School of Health Information Sciences at Houston   (United States)

Author keywords

Breast cancer imaging; Iodine doxorubicin loaded liposome; Mutlifunctional nanoparticle; Personalized medicine; Prediction of chemotherapy

Indexed keywords

DIAGNOSTIC RADIOGRAPHY; ENZYME INHIBITION; MEDICAL IMAGING; ONCOLOGY;

BREAST CANCER IMAGING; IODINE-DOXORUBICIN-LOADED LIPOSOME; MUTLIFUNCTIONAL NANOPARTICLE; PERSONALIZED MEDICINE; PREDICTION OF CHEMOTHERAPY;

TUMORS;

DOXORUBICIN; IODIXANOL; NANOCARRIER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; ENCAPSULATION; FEMALE; MAMMOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RAT; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMOGRAPHY; NANOSTRUCTURES; PROGNOSIS; RATS; SURVIVAL ANALYSIS; TIME FACTORS; WHOLE BODY IMAGING;

ANIMALIA; RATTUS;

EID: 53449089382     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2008.08.036     Document Type: Article

References (48)

1. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23 31 (2005 Nov 1) 7794-7803
2. Lasic D.D. Doxorubicin in sterically stabilized liposomes. Nature 380 6574 (1996 Apr 11) 561-562
3. Yezhelyev M.V., Gao X., Xing Y., Al-Hajj A., Nie S., and O'Regan R.M. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol 7 8 (2006 Aug) 657-667
4. Lasic D.D., and Papahadjopoulos D. Liposomes revisited. Science 267 5202 (1995 Mar 3) 1275-1276
5. Pope-Harman A., Cheng M.M., Robertson F., Sakamoto J., and Ferrari M. Biomedical nanotechnology for cancer. Med Clin North Am 91 5 (2007 Sep) 899-927
6. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5 3 (2005 Mar) 161-171
7. Service R.F. Materials and biology. Nanotechnology takes aim at cancer. Science 310 5751 (2005 Nov 18) 1132-1134
8. Derfus A.M., Chen A.A., Min D.H., Ruoslahti E., and Bhatia S.N. Targeted quantum dot conjugates for siRNA delivery. Bioconjug Chem 18 5 (2007 Sep-Oct) 1391-1396
9. Viglianti B.L., Abraham S.A., Michelich C.R., Yarmolenko P.S., MacFall J.R., Bally M.B., et al. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med 51 6 (2004 Jun) 1153-1162
10. Saul J.M., Annapragada A.V., and Bellamkonda R.V. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J Controlled Release 114 3 (2006 Sep 12) 277-287
11. Hong S., Leroueil P.R., Majoros I.J., Orr B.G., Baker Jr. J.R., and Banaszak Holl M.M. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol 14 1 (2007 Jan) 107-115
12. van de Wiele P., Dierckx R., Scopinaro F., Waterhouse R., Annovazzi A., Kolindou A., et al. Nuclear medicine imaging for prediction or early assessment of response to chemotherapy in patients suffering from breast carcinoma. Breast Cancer Res Treat 72 3 (2002 Apr) 279-286
13. Koning G.A., and Krijger G.C. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery. Anticancer Agents Med Chem 7 4 (2007 Jul) 425-440
14. Torchilin V.P. Multifunctional nanocarriers. Adv Drug Deliv Rev 58 14 (2006 Dec 1) 1532-1555
15. Mitra A., Nan A., Line B.R., and Ghandehari H. Nanocarriers for nuclear imaging and radiotherapy of cancer. Curr Pharm Des 12 36 (2006) 4729-4749
16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 1 (1995 Jan) 27-31
17. Jain R.K. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1 (1999) 241-263
18. Jain R.K. Barriers to drug delivery in solid tumors. Sci Am 271 1 (1994 Jul) 58-65
19. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 46 1-3 (2001 Mar 1) 149-168
20. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Controlled Release 65 1-2 (2000 Mar 1) 271-284
21. Wolff A.C. Liposomal anthracyclines and new treatment approaches for breast cancer. Oncologist 8 Suppl. 2 (2003) 25-30
22. Fukumura D., and Jain R.K. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 101 4 (2007 Jul 1) 937-949
23. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 95 8 (1998 Apr 14) 4607-4612
24. Yuan F., Chen Y., Dellian M., Safabakhsh N., Ferrara N., and Jain R.K. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 93 25 (1996 Dec 10) 14765-14770
25. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 5706 (2005) 58-62
26. Fukumura D., and Jain R.K. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res (2007 May 18)
27. Bolotin E.M., Cohen R., Bar L.K., Emanuel N., Ninio S., Lasic D.D., et al. Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J Liposome Res 4 (1994) 455-479
28. Hubbell J.H., and Seltzer S.M. Tables of X-ray mass attenuation coefficients and mass energy-absorption coefficients. Available from: (1996). http://physics.nist.gov/PhysRefData/XrayMassCoef/cover.html [accessed 12.05.07]
29. Sechopoulos I., Suryanarayanan S., Vedantham S., D'Orsi C., and Karellas A. Computation of the glandular radiation dose in digital tomosynthesis of the breast. Med Phys 34 1 (2007) 221-232
30. Boone J.M. Normalized glandular dose (DgN) coefficients for arbitrary X-ray spectra in mammography: computer-fit values of Monte Carlo derived data. Med Phys 29 5 (2002 May) 869-875
31. Charrois G.J., and Allen T.M. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta 1663 1-2 (2004) 167-177
32. Jabri K.N., and Wilson D.L. Quantitative assessment of image quality enhancement due to unsharp-mask processing in X-ray fluoroscopy. J Opt Soc Am A Opt Image Sci Vis 19 7 (2002 Jul) 1297-1307
33. Brown B.W., Atkinson E.N., Bartoszynski R., Thompson J.R., and Montague E.D. Estimation of human tumor growth rate from distribution of tumor size at detection. J Natl Cancer Inst 72 1 (1984 Jan) 31-38
34. Tewari M., Krishnamurthy A., and Shukla H.S. Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol (2008 May 6)
35. Kao C.Y., Hoffman E.A., Beck K.C., Bellamkonda R.V., and Annapragada A.V. Long-residence-time nano-scale liposomal iohexol for X-ray - based blood pool imaging. Acad Radiol 10 (2003) 475-483
36. Mukundan S., Ghaghada K.B., Badea C.T., Kao C.Y., Hedlund L.W., Provenzale J.M., et al. A liposomal nanoscale contrast agent for preclinical CT in mice. AJR Am J Roentgenol 186 (2006) 300-307
37. Gabizon A., and Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54 Suppl. 4 (1997) 15-21
38. Harrington K.J. Liposomal cancer chemotherapy: current clinical applications and future prospects. Expert Opin Investig Drugs 10 6 (2001 Jun) 1045-1061
39. Harrington K.J., Mohammadtaghi S., Uster P.S., Glass D., Peters A.M., Vile R.G., et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7 2 (2001 Feb) 243-254
40. Northfelt D.W., Martin F.J., Working P., Volberding P.A., Russell J., Newman M., et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 36 1 (1996 Jan) 55-63
41. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8 4 (2002 Apr) 1172-1181
42. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66 (2006) 6732-6740
43. Saucier J.M., Yu J., Gaikwad A., Coleman R.L., Wolf J.K., and Smith J.A. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model. J Oncol Pharm Pract 13 1 (2007 Mar) 39-45
44. Nunes F.L., Schiabel H., and Benatti R.H. Contrast enhancement in dense breast images using the modulation transfer function. Med Phys 29 12 (2002 Dec) 2925-2936
45. Muller M., Mader R.M., Steiner B., Steger G.G., Jansen B., Gnant M., et al. 5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. Cancer Res 57 13 (1997 Jul 1) 2598-2601
46. Blochl-Daum B., Muller M., Meisinger V., Eichler H.G., Fassolt A., and Pehamberger H. Measurement of extracellular fluid carboplatin kinetics in melanoma metastases with microdialysis. Br J Cancer 73 7 (1996 Apr) 920-924
47. Palsmeier R.K., and Lunte C.E. Microdialysis sampling in tumor and muscle: study of the disposition of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (SR 4233). Life Sci 55 10 (1994) 815-825
48. Muller M., Schmid R., Georgopoulos A., Buxbaum A., Wasicek C., and Eichler H.G. Application of microdialysis to clinical pharmacokinetics in humans. Clin Pharmacol Ther 57 4 (1995 Apr) 371-380